Gouveia Miguel, Costa João, Alarcão Joana, Augusto Margarida, Caldeira Daniel, Pinheiro Luís, Vaz Carneiro António, Borges Margarida
Católica Lisbon School of Business and Economics, Universidade Católica Portuguesa, Lisboa, Portugal.
Centro de Estudos de Medicina Baseada na Evidência, Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal; Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal; Unidade de Farmacologia Clínica, Instituto de Medicina Molecular, Lisboa, Portugal.
Rev Port Cardiol. 2015 Jan;34(1):1-11. doi: 10.1016/j.repc.2014.08.005. Epub 2014 Dec 19.
Atrial fibrillation is the most prevalent sustained arrhythmia. This paper estimates the burden and cost of illness attributable to atrial fibrillation in Portugal based on demographic and health statistics.
Mortality data by cause of death came from the European Detailed Mortality Database of the World Health Organization (WHO). Hospital data were taken from the Portuguese diagnosis-related groups database. The burden of disease was measured using DALYs (disability-adjusted life years), a metric adopted by the WHO. Costs studied included resource use and lost productivity. The burden and cost of illness are those attributable to atrial fibrillation and its main complication, ischemic stroke.
In Portugal, 4070 deaths were attributable to atrial fibrillation in 2010, corresponding to 3.8% of all deaths. In total, the burden of disease attributable to atrial fibrillation was estimated at 23,084 DALYs: 10,521 resulting from premature deaths (1.7% of the total DALYs due to death in 2010 in Portugal), and 12,563 resulting from disability. The total estimated direct costs attributable to atrial fibrillation at 2013 prices were €115 million: €34 million for inpatient care and €81 million for outpatient care. Indirect costs resulting from lost production due to disability were estimated at €25 million.
Atrial fibrillation has an important social impact in Portugal due to its associated mortality and morbidity, and was responsible in 2013 for a total cost of €140 million, about 0.08% of gross domestic product.
心房颤动是最常见的持续性心律失常。本文基于人口统计学和健康统计数据，估算了葡萄牙因心房颤动导致的疾病负担和成本。
死因死亡率数据来自世界卫生组织（WHO）的欧洲详细死亡率数据库。医院数据取自葡萄牙诊断相关组数据库。疾病负担采用WHO采用的伤残调整生命年（DALYs）进行衡量。研究的成本包括资源使用和生产力损失。疾病负担和成本是指归因于心房颤动及其主要并发症缺血性中风的部分。
2010年在葡萄牙，4070例死亡归因于心房颤动，占所有死亡人数的3.8%。总体而言，归因于心房颤动的疾病负担估计为23,084个伤残调整生命年：10,521个源于过早死亡（占2010年葡萄牙因死亡导致的总伤残调整生命年的1.7%），12,563个源于残疾。按2013年价格估算，归因于心房颤动的直接成本总计1.15亿欧元：住院护理费用3400万欧元，门诊护理费用8100万欧元。因残疾导致生产损失的间接成本估计为2500万欧元。
心房颤动因其相关的死亡率和发病率在葡萄牙具有重要的社会影响，2013年其总成本达1.4亿欧元，约占国内生产总值的0.08%。
